It's the single most common question patients ask about the new Wegovy tablet: is a needle-free version really as good as the injection? Here's the honest answer, without marketing.

The short answer

The 25mg Wegovy tablet is close to, but slightly below, the 2.4mg Wegovy injection on average weight loss. In head-to-head-comparable data, the tablet delivers around 16.6% average body-weight loss and the injection around 20.7%. Both are large, clinically meaningful losses. The tablet isn't a compromise version; it's a strong option with a small efficacy trade-off in exchange for a needle-free daily routine.

Why there's a gap at all

Semaglutide is a peptide. Peptides don't survive the gut well, only a small percentage of each oral dose actually reaches the bloodstream. That's why the tablet dose (25mg) is more than ten times the injection dose (2.4mg): most of the tablet is metabolised before it can act. Absorption also varies more from day to day than a subcutaneous injection, so the average trial result is slightly lower.

The trial numbers

  • Oral semaglutide 25mg (OASIS-4): ~16.6% average body-weight loss over 64 weeks; roughly 3 in 10 lost ≥20%; placebo ~2.7%.
  • Injectable semaglutide 2.4mg (STEP-1): ~15% average body-weight loss over 68 weeks; comparable analyses put on-treatment loss around 20.7%.
  • Injectable semaglutide 7.2mg (STEP UP): up to ~21% in people who reached and maintained the highest dose (about 18.7% on a treatment-policy basis).

What matters more than the trial average

Adherence. The best medicine is the one you'll actually take on schedule for a year or more. If needles are a genuine block for you, the tablet's slightly lower average loss will beat the injection's higher average loss you never quite start. On the other hand, if you can't reliably keep a 30-minute empty-stomach window in the morning, the injection will beat the tablet you keep taking wrongly.

When the tablet is the better choice

  • You're needle-averse and it's been the reason you've put off treatment.
  • You want a daily habit, the morning tablet is easy to attach to an existing routine.
  • You value the flexibility of stopping cleanly at the end of a 30-tablet pack.

When the injection is the better choice

  • You have cardiovascular risk factors and want the licensed CV benefit at 2.4mg (SELECT trial).
  • You want the highest-efficacy semaglutide option (7.2mg).
  • Your mornings can't reliably accommodate the empty-stomach rule.

Pricing rises with each dose step, so the honest cost picture depends on where you settle. For the full per-dose breakdown, see current UK Wegovy tablet prices, or read the full titration schedule to see how long you'd spend at each step.

Update, August 2026: a second weight loss tablet, Foundayo (orforglipron), was approved by the MHRA on 10 August 2026. It has no fasting or timing rules at all, which changes the tablet versus injection trade-off again. It is not on sale yet, but you can read our full Foundayo guide and join the UK waitlist, or see how it compares to Wegovy tablets.

Frequently asked questions

Are Wegovy tablets as effective as the injection? They're close, but not identical. In head-to-head data, the 25mg tablet delivered around 16.6% average weight loss vs about 20.7% for the 2.4mg injection over comparable periods. Both are large, meaningful losses.

Why is the tablet slightly less effective? Oral semaglutide is poorly absorbed, only a small fraction of each dose reaches the bloodstream. That's why the tablet dose (up to 25mg) is much higher than the injection (2.4mg). Absorption also varies more day-to-day, which affects average results.

Who is the tablet a good choice for? Needle-averse patients, people who prefer a daily routine, and anyone who can reliably protect a 30-minute empty-stomach window in the morning. Long-term adherence to any medicine you'll actually take beats a stronger option you won't.

Can I switch from tablet to injection later? Yes. A pharmacist-led switch is possible. It's a clinical decision based on tolerance, response and preference.

Do the side effects differ? Broadly the same profile, nausea, constipation, diarrhoea, indigestion, mostly during dose increases. The tablet can cause slightly more upper-GI symptoms because absorption happens directly in the stomach.

References

  1. Wharton S, et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS-4). N Engl J Med 2025.
  2. Wilding JPH, et al. Once-weekly semaglutide 2.4 mg (STEP-1). N Engl J Med 2021.
  3. Wharton S, et al. Once-weekly semaglutide 7·2 mg (STEP UP). Lancet Diabetes Endocrinol 2025.

Reviewed by Jimah Alsaai MPharm, GPhC 2232652, Superintendent Pharmacist, Solira.